

PRESS RELEASE

GEA to Present Continuous OSD Processing Solutions at AAPS in Denver, USA

Düsseldorf (Germany), October 25, 2016 – GEA will showcase its innovative manufacturing technology for the production of pharmaceutical oral dosage forms (OSDs) at the upcoming AAPS (American Association of Pharmaceutical Scientists) Meeting and Expo. The 2016 AAPS conference will take place at Colorado Convention Center in Denver, USA, November 13-17.

Taking center stage will be GEA's continuous ConsiGma™ platform, the company's multipurpose platform that has been designed to transfer powder into coated tablets in development, pilot, clinical and production volumes in a single integrated unit.

In a 2015 collaboration with Vertex (Boston, Massachusetts), the US Food and Drug Administration (FDA) designated a life-saving breakthrough therapy, developed and commercially manufactured for the first time ever on a continuous basis using GEA's ConsiGma™ continuous manufacturing technology. ConsiGma™ technology further became a fundamental part of the Pfizer PCMM (Portable, Continuous, Miniature and Modular) system and winner of international equipment innovation awards at Interphex, New York City in 2015, ISPE FOYA, Washington DC in 2016 and CPhI Worldwide, Barcelona, Spain in 2016.

In addition, GEA's flexible, small-scale fluid bed processing unit, AirConnect™, will also be on display. The AirConnect™ multiprocessor from GEA offers infinite fluid bed processing possibilities for small-scale applications. The service unit provides the main air treatment and control facilities and a range of optional modules deliver unlimited processing options, including fluid bed drying, granulation and coating.

At the event, GEA experts will be available to discuss the company's Pharmaceutical Test Centers, including the test facility in Columbia, MD. These centers enable customers to see, first-hand, GEA's comprehensive range of capabilities and solutions, and how they can be integrated into their existing business operations.

Lastly, GEA will spotlight its pharmaceutical spray drying solutions. Spray drying is a technique preferred by a growing number of pharmaceutical companies to produce better drugs. This ultrafast and gentle drying technology offers unique ways to define particle characteristics and improve drug pharmacokinetics.

To arrange an appointment with the GEA team or request further information, please contact us at pharma@gea.com.

PRESS RELEASE

Corporate Media & Press:

Lilian Schmalenstroer

Peter-Müller-Str. 12, 40468 Düsseldorf, Germany

Phone +49 2522 772174

lilian.schmalenstroer@gea.com

In case of publication, please submit two copies of each of the published items for our archives.

About GEA

GEA is one of the largest suppliers for the food processing industry and a wide range of process industries that generated consolidated revenues of approximately EUR 4.6 billion in 2015. As an international technology group, the Company focuses on process technology and components for sophisticated production processes in various end-user markets. The Group generates more than 70 percent of its revenue in the food sector that enjoys long-term sustainable growth. As of June 30, 2016, the Company employed over 17,000 people worldwide. GEA is a market and technology leader in its business areas. The Company is listed in Germany's MDAX (G1A, WKN 660 200). In addition, GEA's share is a constituent of the MSCI Global Sustainability Indexes. Further information is available on the Internet at gea.com.

If you do not want to receive any further information from GEA, please send an email to pr@gea.com.